Ama Dedo Okyere1, Jianliang Song1, Viren Patwa1, Rhonda L Carter1, Nitya Enjamuri1, Anna Maria Lucchese1, Jessica Ibetti1, Claudio de Lucia1,2, Sarah M Schumacher1,3, Walter J Koch1, Joseph Y Cheung1, Jeffrey L Benovic4, Douglas G Tilley5. 1. Center for Translational Medicine, Lewis Katz School of Medicine, Temple University, Room 945A MERB, 3500 N. Broad St, Philadelphia, PA, 19140, USA. 2. Instituti Clinici Scientifici Maugeri di Telese Terme, Telese Terme, Italy. 3. Cleveland Clinic Lerner College of Medicine, Cleveland, OH, USA. 4. Department of Biochemistry and Molecular Biology, Thomas Jefferson University, Philadelphia, PA, 19107, USA. 5. Center for Translational Medicine, Lewis Katz School of Medicine, Temple University, Room 945A MERB, 3500 N. Broad St, Philadelphia, PA, 19140, USA. douglas.tilley@temple.edu.
Abstract
PURPOSE: β-Adrenergic receptors (βAR) are essential targets for the treatment of heart failure (HF); however, chronic use of βAR agonists as positive inotropes to increase contractility in a Gs protein-dependent manner is associated with increased mortality. Alternatively, we previously reported that allosteric modulation of β2AR with the pepducin intracellular loop (ICL)1-9 increased cardiomyocyte contractility in a β-arrestin (βarr)-dependent manner, and subsequently showed that ICL1-9 activates the Ras homolog family member A (RhoA). Here, we aimed to elucidate both the proximal and downstream signaling mediators involved in the promotion of cardiomyocyte contractility in response to ICL1-9. METHODS: We measured adult mouse cardiomyocyte contractility in response to ICL1-9 or isoproterenol (ISO, as a positive control) alone or in the presence of inhibitors of various potential components of βarr- or RhoA-dependent signaling. We also assessed the contractile effects of ICL1-9 on cardiomyocytes lacking G protein-coupled receptor (GPCR) kinase 2 (GRK2) or 5 (GRK5). RESULTS: Consistent with RhoA activation by ICL1-9, both Rho-associated protein kinase (ROCK) and protein kinase D (PKD) inhibition were able to attenuate ICL1-9-mediated contractility, as was inhibition of myosin light chain kinase (MLCK). While neither GRK2 nor GRK5 deletion impacted ICL1-9-mediated contractility, pertussis toxin attenuated the response, suggesting that ICL1-9 promotes downstream RhoA-dependent signaling in a Gi protein-dependent manner. CONCLUSION: Altogether, our study highlights a novel signaling modality that may offer a new approach to the promotion, or preservation, of cardiac contractility during HF via the allosteric regulation of β2AR to promote Gi protein/βarr-dependent activation of RhoA/ROCK/PKD signaling.
PURPOSE: β-Adrenergic receptors (βAR) are essential targets for the treatment of heart failure (HF); however, chronic use of βAR agonists as positive inotropes to increase contractility in a Gs protein-dependent manner is associated with increased mortality. Alternatively, we previously reported that allosteric modulation of β2AR with the pepducin intracellular loop (ICL)1-9 increased cardiomyocyte contractility in a β-arrestin (βarr)-dependent manner, and subsequently showed that ICL1-9 activates the Ras homolog family member A (RhoA). Here, we aimed to elucidate both the proximal and downstream signaling mediators involved in the promotion of cardiomyocyte contractility in response to ICL1-9. METHODS: We measured adult mouse cardiomyocyte contractility in response to ICL1-9 or isoproterenol (ISO, as a positive control) alone or in the presence of inhibitors of various potential components of βarr- or RhoA-dependent signaling. We also assessed the contractile effects of ICL1-9 on cardiomyocytes lacking G protein-coupled receptor (GPCR) kinase 2 (GRK2) or 5 (GRK5). RESULTS: Consistent with RhoA activation by ICL1-9, both Rho-associated protein kinase (ROCK) and protein kinase D (PKD) inhibition were able to attenuate ICL1-9-mediated contractility, as was inhibition of myosin light chain kinase (MLCK). While neither GRK2 nor GRK5 deletion impacted ICL1-9-mediated contractility, pertussis toxin attenuated the response, suggesting that ICL1-9 promotes downstream RhoA-dependent signaling in a Gi protein-dependent manner. CONCLUSION: Altogether, our study highlights a novel signaling modality that may offer a new approach to the promotion, or preservation, of cardiac contractility during HF via the allosteric regulation of β2AR to promote Gi protein/βarr-dependent activation of RhoA/ROCK/PKD signaling.
Authors: Bryan S Yung; Cameron S Brand; Sunny Y Xiang; Charles B B Gray; Christopher K Means; Hugh Rosen; Jerold Chun; Nicole H Purcell; Joan Heller Brown; Shigeki Miyamoto Journal: J Mol Cell Cardiol Date: 2016-12-23 Impact factor: 5.000
Authors: D F Anthony; Y Y Sin; S Vadrevu; N Advant; J P Day; A M Byrne; M J Lynch; G Milligan; M D Houslay; G S Baillie Journal: Mol Cell Biol Date: 2010-12-20 Impact factor: 4.272
Authors: Philip W Raake; Leif E Vinge; Erhe Gao; Matthieu Boucher; Giuseppe Rengo; Xiongwen Chen; Brent R DeGeorge; Scot Matkovich; Steven R Houser; Patrick Most; Andrea D Eckhart; Gerald W Dorn; Walter J Koch Journal: Circ Res Date: 2008-07-17 Impact factor: 17.367
Authors: Laurel A Grisanti; Toby P Thomas; Rhonda L Carter; Claudio de Lucia; Erhe Gao; Walter J Koch; Jeffrey L Benovic; Douglas G Tilley Journal: Theranostics Date: 2018-09-09 Impact factor: 11.556